Tatman J L, Freedman R S, Scott W, Atkinson E N
Department of Gynecology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Eur J Cancer Clin Oncol. 1989 Nov;25(11):1619-21. doi: 10.1016/0277-5379(89)90307-6.
Fifteen patients with recurrent or progressive endometrial adenocarcinoma of moderate to poor histologic differentiation were entered in a phase II trial of sequentially administered oral ethinyl estradiol and medroxyprogesterone acetate. There were no significant clinical responses in 12 patients evaluated for response and four patients experienced thromboembolic complications. This cyclic treatment regimen is considered ineffective for this patient population at the dosages and schedules used.
15例组织学分化程度为中至差的复发性或进展性子宫内膜腺癌患者进入了一项口服炔雌醇和醋酸甲羟孕酮序贯给药的II期试验。在评估反应的12例患者中没有显著的临床反应，4例患者出现了血栓栓塞并发症。按照所使用的剂量和疗程，这种周期性治疗方案被认为对该患者群体无效。
